Treat metastatic castrate prostate cancer therapy dose 2 of 6

Ended Awarded

Contract number
HT009021FG0610007
Awardee
Awarding agency
Obligated
$12,407

Award facts

Contract value 100% obligated
$12,407.38 Current and potential, with all options
Completion date
Current and potential, with all options
NAICS code
325412 Pharmaceutical Preparation Manufacturing
PSC
6515 Medical And Surgical Instruments, Equipment, And Supplies
Set-aside
No set-aside
Competition
Competed under SAP · 3 offers Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Dublin, OH 43017, USA

Award details come from SAM.gov/FPDS.

About this award

Cardinal Health 414, LLC, a subsidiary of Cardinal Health, Inc., has been awarded a firm fixed price blanket purchase agreement call against an unspecified multiple award contract vehicle to provide metastatic castrate-resistant prostate cancer therapy. The $12,407.38 potential value contract was awarded by the Defense Health Agency on June 16, 2021, with a completion date of the same. Performance will take place in Dublin, Ohio. No set-aside provisions were applied to this award to treat metastatic castrate prostate cancer for a dose of six treatments.

Quick answers

Who was awarded contract HT009021FG0610007?

HT009021FG0610007 was awarded to Cardinal Health 414, LLC by Defense Health Agency (Department of Defense) on June 16, 2021.

How much is contract HT009021FG0610007 worth?

The government has obligated $12,407 on HT009021FG0610007.

Is contract HT009021FG0610007 an order under another contract?

Yes. HT009021FG0610007 is a BPA call under HT001420A0031, a blanket purchase agreement.

Was contract HT009021FG0610007 competed?

The extent of competition for HT009021FG0610007 was competed under sap. The government received 3 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award